UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 193

Sortiert nach

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Nature communications, 2022-01, Vol.13 (1), p.69-69, Article 69

2022

Link zum Volltext

Verfügbarkeit prüfen

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Journal of clinical oncology, 2012-03, Vol.30 (7), p.709-717

2012

Link zum Volltext

Verfügbarkeit prüfen

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

International journal of cancer, 2015-07, Vol.137 (1), p.96-103

2015

Link zum Volltext

Verfügbarkeit prüfen

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1580-1583

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

BMC cancer, 2012-01, Vol.12 (1), p.39-39, Article 39

2012

Link zum Volltext

Verfügbarkeit prüfen

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Trends in cancer, 2021-03, Vol.7 (3), p.181-185

Lønning, Per E

2021

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Link zum Volltext

Verfügbarkeit prüfen

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NMR in biomedicine, 2012-02, Vol.25 (2), p.369-378

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5126-5137

2005

Link zum Volltext

Verfügbarkeit prüfen

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Cancer & metabolism, 2019-06, Vol.7 (1), p.6-6, Article 6

2019

Link zum Volltext

Verfügbarkeit prüfen

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

Oncotarget, 2011-03, Vol.2 (3), p.251-258

2011

Link zum Volltext

Verfügbarkeit prüfen

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Acta oncologica, 2014-10, Vol.53 (10), p.1347-1355

2014

Link zum Volltext

Verfügbarkeit prüfen

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Therapeutic Advances in Medical Oncology, 2012-05, Vol.4 (3), p.127-137

Lønning, Per E.

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Transcription, 2011-09, Vol.2 (5), p.207-210

2011

Link zum Volltext

Verfügbarkeit prüfen

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Oncotarget, 2017-06, Vol.8 (25), p.41227-41241

2017

Link zum Volltext

Verfügbarkeit prüfen

Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594

Lab on a chip, 2017-09, Vol.17 (18), p.3186-3187

Lønning, Per E

2017

Link zum Volltext

Verfügbarkeit prüfen

Chemosensitivity and p53; new tricks by an old dog

Breast cancer research : BCR, 2012-11, Vol.14 (6), p.325-325, Article 325

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of aromatase inhibitors on bone health in breast cancer patients

Journal of steroid biochemistry and molecular biology, 2010-02, Vol.118 (4), p.294-299

2010

Link zum Volltext

Verfügbarkeit prüfen

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk

PloS one, 2012-04, Vol.7 (4), p.e36263-e36263

2012

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4859-4861

Lønning, Per E

2008

Link zum Volltext

Verfügbarkeit prüfen

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Biochimica et biophysica acta, 2013-03, Vol.1830 (3), p.2790-2797

2013

Link zum Volltext

Verfügbarkeit prüfen

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Translational oncology, 2017-10, Vol.10 (5), p.806-817

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Scientific reports, 2021-12, Vol.11 (1), p.23463-23463, Article 23463

2021

Link zum Volltext

Verfügbarkeit prüfen

Recent data on intratumor estrogens in breast cancer

Steroids, 2011-07, Vol.76 (8), p.786-791

2011

Link zum Volltext

Verfügbarkeit prüfen

Endocrine effects of aromatase inhibitors

Journal of clinical oncology, 2010-02, Vol.28 (6), p.e101-e102

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 193

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(185)
Mit Volltextzugriff
(174)

Publikationsform

Artikel
(192)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Chemosensitivity and p53; new tricks by an old dog

Impact of aromatase inhibitors on bone health in breast cancer patients

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Recent data on intratumor estrogens in breast cancer

Endocrine effects of aromatase inhibitors

Aktive Filter

Suchergebnisse filtern